Advanced Cancer Therapeutics’ PFK-158 Featured in CEO/CFO Magazine; Announces MD Anderson and UT Health Science Center San Antonio Added as Clinical Trial Sites
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, has been featured in the December 15, 2014 issue of CEO/CFO Magazine in which ACT President and CEO Randall B. Riggs discusses PFK-158, a first-in-man/first-in-class inhibitor of PFKFB3, an enzyme that controls glycolysis and that is overexpressed in most hematological and solid tumors. - December 17, 2014
Advanced Cancer Therapeutics’ PFK-158 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, has been chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch” for its compound, PFK-158. PFK-158 is a small... - November 27, 2014
ACT Enters Phase I Human Clinical Trials with First-in-Class Anti-Cancer Drug Candidate
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, announced today that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in... - June 04, 2014
U.S. Granted Patent 8,088,385 B2 Strengthens Advanced Cancer Therapeutics’ Anti-Cancer Product Portfolio
Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has been granted U.S. Patent 8,088,385 B2 titled “PFKFB3 inhibitor for the treatment of a Proliferative Cancer” by the United States Patent... - April 04, 2012
Advanced Cancer Therapeutics Chief Scientific Officer to Present Preclinical Data on Glycolysis Inhibitors at World Cancer Metabolism Summit
Advanced Cancer Therapeutics, LLC (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that Dr. Gilles Tapolsky, ACT’s Chief Scientific Officer, has been selected to present at the World Cancer Metabolism Summit to be held February 1 – February 2, 2012 in Washington, D.C. - February 01, 2012
Advanced Cancer Therapeutics CEO to Present Preclinical Data on Cancer Metabolism Drug at MidAmerica Healthcare Venture Forum
Advanced Cancer Therapeutics, LLC (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that Randall B. Riggs, President & CEO, has been selected to present at the 9th Annual MidAmerica Healthcare Venture Forum to be held at the... - October 20, 2011